MedTrace Logo

rEEG Guided Pharmacotherapy of Subjects With Depression Treatment Failure

NCT00437827 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2009-10-27

No results posted yet for this study

Summary

This study is testing a process (rEEG)for selecting the most appropriate medication(s) to treat a patient's depression versus a control group being treated according to a standardized method, the modified Star\*D Algorithm. Qualified subjects will be randomized to the experimental (rEEG guided) group, or the control group and treated for 12 weeks. Medications utilized in this study are currently marketed. All visits, physical exam, rEEG, labs, rating scales and medications are provided at no cost to the patient.

Conditions

  • Depressive Disorder

Interventions

OTHER

Star*D algorithm

Standard of care based upon the therapies selected in the Star\*D study.

OTHER

rEEG-guided therapy

An rEEG report is based upon a process that utilizes a patient's drug-free QEEG to predict successful treatment strategies.

Sponsors & Collaborators

  • MYnd Analytics

    lead INDUSTRY

Principal Investigators

  • Charles DeBattista, MD · Stanford University

  • Gustavo Kinrys, M.D. · Cambridge Hospital

  • Steven G Potkin, MD · University of California, Irvine

  • Daniel Hoffman, MD · MYnd Analytics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-08-31
Primary Completion
2009-10-31
Completion
2009-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00437827 on ClinicalTrials.gov